1. Home
  2. VELO vs DCTH Comparison

VELO vs DCTH Comparison

Compare VELO & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Velo3D Inc.

VELO

Velo3D Inc.

HOLD

Current Price

$11.48

Market Cap

495.9M

Sector

Technology

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$12.92

Market Cap

398.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VELO
DCTH
Founded
2014
1988
Country
United States
United States
Employees
134
N/A
Industry
Industrial Machinery/Components
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
495.9M
398.7M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
VELO
DCTH
Price
$11.48
$12.92
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$18.00
$22.00
AVG Volume (30 Days)
1.7M
332.2K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
107.53
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$42.22
$24.54
Revenue Next Year
$50.08
$33.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.87
$8.12
52 Week High
$31.75
$13.74

Technical Indicators

Market Signals
Indicator
VELO
DCTH
Relative Strength Index (RSI) 44.90 57.28
Support Level $8.33 $9.98
Resistance Level $11.92 $13.74
Average True Range (ATR) 1.19 0.50
MACD 0.29 -0.07
Stochastic Oscillator 61.15 77.65

Price Performance

Historical Comparison
VELO
DCTH

About VELO Velo3D Inc.

Velo3D Inc provides additive manufacturing (AM), also referred to as three-dimensional printing (3D printing), to deliver breakthroughs in performance, cost, and time in the production of high-value metal parts. The Velo3D intelligent metal additive manufacturing solution is comprised of the Velo3D Flow intelligent print preparation software, the Sapphire production system, and Velo3D Assure, real-time quality assurance software. Its complete manufacturing solution enables clients to build the parts needed, speed their development, and reduce their product costs.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: